Publisher Summary Long acting β 2-adrenoceptor agonists are a highly precedented drug
class used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) …

The introduction of long-acting beta agonists (LABAs) was considered a major advance in
bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use …

Background The addition of a long acting beta agonist (LABA) to inhaled corticosteroid (ICS)
therapy can improve asthma symptoms and reduce exacerbations. The addition of LABA …

Asthma ranks among the most common of chronic diseases in the Western world. Although
modern therapy has improved patient care, asthma still affects 5–10% of the population and …

BACKGROUND: After the Serevent Nationwide Surveillance clinical trial, controversy has
surrounded the safety of long-acting beta agonists (LABAs). OBJECTIVE: Examine the …

In the last two decades several significant changes have been proposed in the receptor
theory that describes how ligands can interact with G protein‐coupled receptors (GPCRs) …

Background In asthma, short-and long-acting β-agonists (SABAs and LABAs) should be
used together with inhaled corticosteroids (ICS), and regular use is inappropriate. Objective …

Asthma was originally thought to be associated with an intrinsic defect in β 2ADR (β 2-
adrenoceptor) function, tipping the balance towards parasympathetic bronchoconstriction …

Background The safe and appropriate use of long-acting beta-agonists (LABAs) for the
treatment of asthma has been widely debated. In two large clinical trials, investigators found …

Background Because of concerns about the safety of long-acting β 2-agonist (LABA) use in
patients with asthma, withdrawal of the LABA is recommended by the US Food and Drug …